Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization 2023-11-28 19:00
Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore 2023-10-18 20:00
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. 2023-10-04 04:25
Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall 2023-06-16 06:05
Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore 2023-05-12 21:01
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses 2023-05-09 18:28
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine 2023-02-13 21:00
Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster 2023-01-18 21:00
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates 2022-12-30 21:00
Novavax Announces Pricing of $65 Million Public Offering of Common Stock 2022-12-16 14:49
Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes 2022-12-16 14:18
Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes 2022-12-15 23:43
Novavax Announces Proposed $125 Million Public Offering of Common Stock 2022-12-15 05:39
Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster 2022-11-08 21:00
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults 2022-10-22 03:25
Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants 2022-10-12 21:35
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17 2022-08-22 10:05
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17 2022-08-18 21:06
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults 2022-08-17 20:00
Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17 2022-08-12 21:39
1 2 3 4